One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab), which was approved by the FDA for the same HCC indication in September 2017.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.